Featured Research

from universities, journals, and other organizations

Developmental delays in children following prolonged seizures

Date:
April 8, 2013
Source:
Wiley
Summary:
Researchers have determined that developmental delays are present in children within six weeks following convulsive status epilepticus (CSE)—a seizure lasting longer than thirty minutes. The study suggests that neurodevelopmental impairments continue to be present one year after CSE.

Researchers from the UK determined that developmental delays are present in children within six weeks following convulsive status epilepticus (CSE) -- a seizure lasting longer than thirty minutes. The study appearing today in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy (ILAE), suggests that neurodevelopmental impairments continue to be present one year after CSE.

CSE is one of the most common neurological emergencies in children. These prolonged seizures can occur with or without fevers (febrile). Studies show that CSE occurs more frequently during the first three years of life -- a time of critical growth and development in children. Prior research investigating CSE has focused mainly on simple febrile seizures and was conducted years after the event occurred.

"Our study is the first to examine cognitive, language, and motor function in children within six weeks of CSE, with follow-up at one year to determine their developmental track," said lead author, Dr. Marina Martinos with the Developmental Cognitive Neurosciences Unit at UCL Institute of Child Health in London. "Understanding how CSE impacts early childhood development and whether this type of seizure has long-term adverse affects is an important addition to medical evidence."

For the present study, researchers recruited 54 children between one and forty-two months of age who had at least one CSE event. CSE episodes were classified as prolonged febrile seizures (PFS) or nonfebrile CSE. All pediatric participants underwent neuropsychological assessments and imaging scans within six weeks of the CSE event and at one year. Developmental skills were measured in children who had seizures and compared to children without seizures with normal development.

Half of the pediatric participants had PFS and the other half had nonfebrile CSE, with assessments carried out at a mean of 38 days following CSE. Findings indicate that CSE is linked to developmental impairments within six weeks of the event, and that the impairments persisted at the one-year follow-up. Children with nonfebrile PFS had worse developmental outcomes than those with PFS, and children in the PFS group had poorer developmental skills than those in the control group. The authors found that seizure characteristics (e.g. duration) were not a significant predictor of developmental performance.

Dr. Martinos concludes, "We found developmental impairments in children following CSE, including those with PFS who normally do not display neurologic issues prior to the seizure. The fact that neurodevelopmental impairments are still present at one year after the episode suggests that the CSE event is not having just a transient effect on developmental abilities. The CSE may have a longer lasting impact on future development through a more permanent reorganization of functional brain networks -- a reorganization that may have already taken place when we first assess these children."

Alternatively, the authors comment, these data suggest that the neurodevelopmental impairments observed predate the seizure even in those with no neurological priors. The authors propose that further studies that include neurocognitive techniques are necessary to enhance understanding of the long-term impact of CSE on child development.


Story Source:

The above story is based on materials provided by Wiley. Note: Materials may be edited for content and length.


Journal Reference:

  1. Marina M. Martinos, Michael Yoong, Shekhar Patil, Wui K. Chong, Rodica Mardari, Richard F. M. Chin, Brian G. R. Neville, Michelle de Haan, Rod C. Scott. Early developmental outcomes in children following convulsive status epilepticus: A longitudinal study. Epilepsia, 2013; DOI: 10.1111/epi.12136

Cite This Page:

Wiley. "Developmental delays in children following prolonged seizures." ScienceDaily. ScienceDaily, 8 April 2013. <www.sciencedaily.com/releases/2013/04/130408085048.htm>.
Wiley. (2013, April 8). Developmental delays in children following prolonged seizures. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/04/130408085048.htm
Wiley. "Developmental delays in children following prolonged seizures." ScienceDaily. www.sciencedaily.com/releases/2013/04/130408085048.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins